Cesca Therapeutics Inc. (NASDAQ: KOOL) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine, according to the company’s website (see here: www.CescaTherapeutics.com). SNNLive spoke with Kenneth Harris, President, and Robin Stracey, Director and CEO of Cesca Therapeutics, Inc., at the Marcum MicroCap Conference 2015 in New York City, NY and at the LD Micro Invitational 2015 in Bel Air, CA, respectively. In this article, we’ll be highlighting both video interviews with Cesca Therapeutics.
We first spoke with Kenneth Harris at the Marcum MicroCap Conference 2015, who provides an update since our last interview (see here: $KOOL - Q1/2015 Video Update with Cesca Therapeutics, Inc.), “We’ve progressed our CLI trial. We’ve re-submitted to the FDA – we did that two weeks ago, and we expect to have a response from them for a pivotal Phase 3 trial to be done here in the US; its 60 sites in the next couple of weeks because they have 30 days to respond.” Mr. Harris goes on to explain what this means to the Company, and their clinical development.
Mr. Harris then discusses how the Company received IEC/IRB approval to initiate Phase 2 AMI study (Click HERE for Announcement), collaboration with Cook Medical, steps to getting the Company’s therapeutics to market, bone marrow transplant program, and his background.
We then spoke with Cesca’s CEO, Robin Stracey at the LD Micro Invitational 2015, who began with a brief overview of the company and then gets into his background. Mr. Stracey explains how his focus is on, as he states, “merger-related activities,” as well as his insights into 2015-2016.
Since speaking with Mr. Harris and Mr. Stracey, the company has made the following announcements:
For more information about Cesca Therapeutics, go to: www.CescaTherapeutics.com
© 2017 Stock News Now
Supported by Superior Web Solutions